Outcomes and Long-Term Effects of COVID-19 in Patients with Inflammatory Bowel Diseases – A Danish Prospective Population-Based Cohort Study with Individual-Level Data
Uloženo v:
| Název: | Outcomes and Long-Term Effects of COVID-19 in Patients with Inflammatory Bowel Diseases – A Danish Prospective Population-Based Cohort Study with Individual-Level Data |
|---|---|
| Autoři: | Mohamed Attauabi, Jens Frederik Dahlerup, Anja Poulsen, Malte Rosager Hansen, Marianne Kajbæk Vester-Andersen, Sule Eraslan, August Pilegaard Prahm, Natalia Pedersen, Lone Larsen, Tine Jess, Anders Neumann, Kent V Haderslev, Akbar Molazahi, Anders Berg Lødrup, Henning Glerup, Asser Mathiassen Oppfeldt, Michael Dam Jensen, Klaus Theede, Marianne Kiszka-Kanowitz, Jakob Benedict Seidelin, Johan Burisch |
| Zdroj: | Attauabi, M, Dahlerup, J F, Poulsen, A, Hansen, M R, Verner-Andersen, M K, Eraslan, S, Prahm, A P, Pedersen, N, Larsen, L, Jess, T, Neumann, A, Haderslev, K V, Molazahi, A, Lødrup, A B, Glerup, H, Oppfeldt, A M, Jensen, M D, Theede, K, Kiszka-Kanowitz, M, Seidelin, J B, Burisch, J & the Danish COVID-IBD Study Group 2022, 'Outcomes and long-term effects of COVID-19 in patients with inflammatory bowel diseases-a Danish prospective population-based cohort study with individual-level data', Journal of Crohn's & colitis, vol. 16, no. 5, jjab192, pp. 757–767. https://doi.org/10.1093/ecco-jcc/jjab192 Attauabi, M, Dahlerup, J F, Poulsen, A, Hansen, M R, Vester-Andersen, M K, Eraslan, S, Prahm, A P, Pedersen, N, Larsen, L, Jess, T, Neumann, A, Haderslev, K V, Molazahi, A, Lødrup, A B, Glerup, H, Oppfeldt, A M, Jensen, M D, Theede, K, Kiszka-Kanowitz, M, Seidelin, J B, Burisch, J & Danish COVID-IBD Study Group 2022, 'Outcomes and Long-Term Effects of COVID-19 in Patients with Inflammatory Bowel Diseases-A Danish Prospective Population-Based Cohort Study with Individual-Level Data', Journal of Crohn's & Colitis, vol. 16, no. 5, pp. 757-767. https://doi.org/10.1093/ecco-jcc/jjab192 |
| Informace o vydavateli: | Oxford University Press (OUP), 2021. |
| Rok vydání: | 2021 |
| Témata: | Denmark, COVID-19, Inflammatory bowel diseases, Colitis, Inflammatory Bowel Diseases, Inflammatory Bowel Diseases/complications, Denmark/epidemiology, Crohn Disease/complications, population-based, Colitis, Ulcerative/diagnosis, 3. Good health, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Crohn Disease, Humans, Ulcerative/diagnosis, Colitis, Ulcerative, COVID-19 outcomes and sequelae, Prospective Studies, COVID-19/epidemiology |
| Popis: | Background and AimsThe health consequences of coronavirus disease 2019 [COVID-19] among patients with ulcerative colitis [UC] and Crohn’s disease [CD] remain largely unknown. We aimed to investigate the outcomes and long-term effects of COVID-19 in patients with UC or CD.MethodsWe conducted a prospective, population-based study covering all Danish patients with CD or UC and confirmed COVID-19 between January 28, 2020 and April 1, 2021, through medical records and questionnaires.ResultsAll 319 patients with UC and 197 patients with CD who developed COVID-19 in Denmark were included in this study and compared with the Danish background population with COVID-19 [N = 230 087]. A significantly higher risk of COVID-19-related hospitalization was observed among patients with UC (N = 46 [14.4%], relative risk [RR] = 2.49 [95% confidence interval, CI, 1.91–3.26]) and CD (N = 24 [12.2%], RR = 2.11 [95% CI 1.45–3.07]) as compared with the background population (N = 13 306 [5.8%]). A similar pattern was observed for admission to intensive care (UC: N = 8 [2.51%], RR = 27.88 [95% CI 13.88–56.00]; CD: N = 3 [1.52%], RR = 16.92 [95% CI 5.46–52.46]). After a median of 5.1 months (interquartile range [IQR] 4.5–7.9), 58 [42.3%] and 39 [45.9%] patients with UC and CD, respectively, reported persisting symptoms which were independently associated with discontinuation of immunosuppressive therapies during COVID-19 (odds ratio [OR] = 1.50 [95% CI 1.07–10.22], p = 0.01) and severe COVID-19 (OR = 2.76 [95% CI 1.05–3.90], p = 0.04), but not with age or presence of comorbidities.ConclusionIn this population-based study of 516 patients with IBD and COVID-19, 13.6% needed hospitalization and 2.1% required intensive care. Furthermore, sequelae were frequent, affecting 43.7% of COVID-19-infected patients. These findings might have implications for planning the healthcare of patients in the post-COVID-19 era. |
| Druh dokumentu: | Article |
| Jazyk: | English |
| ISSN: | 1876-4479 1873-9946 |
| DOI: | 10.1093/ecco-jcc/jjab192 |
| Přístupová URL adresa: | https://academic.oup.com/ecco-jcc/advance-article-pdf/doi/10.1093/ecco-jcc/jjab192/41297798/jjab192.pdf https://pubmed.ncbi.nlm.nih.gov/34755858 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689957/pdf/jjab192.pdf https://vbn.aau.dk/da/publications/085933f1-8b1a-4a20-bb1e-97f3a3710eb6 http://www.scopus.com/inward/record.url?scp=85133100715&partnerID=8YFLogxK https://doi.org/10.1093/ecco-jcc/jjab192 https://portal.findresearcher.sdu.dk/da/publications/d3d528be-e10b-41c7-aaad-0c3a82532b08 https://doi.org/10.1093/ecco-jcc/jjab192 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8689957/pdf/jjab192.pdf https://pure.au.dk/portal/en/publications/6538143e-9b84-4ffd-bbe6-2441fae84afc https://doi.org/10.1093/ecco-jcc/jjab192 |
| Rights: | OUP Standard Publication Reuse |
| Přístupové číslo: | edsair.doi.dedup.....65a5890016b3b0e98e6ebf85d3a910be |
| Databáze: | OpenAIRE |
Nájsť tento článok vo Web of Science | Abstrakt: | Background and AimsThe health consequences of coronavirus disease 2019 [COVID-19] among patients with ulcerative colitis [UC] and Crohn’s disease [CD] remain largely unknown. We aimed to investigate the outcomes and long-term effects of COVID-19 in patients with UC or CD.MethodsWe conducted a prospective, population-based study covering all Danish patients with CD or UC and confirmed COVID-19 between January 28, 2020 and April 1, 2021, through medical records and questionnaires.ResultsAll 319 patients with UC and 197 patients with CD who developed COVID-19 in Denmark were included in this study and compared with the Danish background population with COVID-19 [N = 230 087]. A significantly higher risk of COVID-19-related hospitalization was observed among patients with UC (N = 46 [14.4%], relative risk [RR] = 2.49 [95% confidence interval, CI, 1.91–3.26]) and CD (N = 24 [12.2%], RR = 2.11 [95% CI 1.45–3.07]) as compared with the background population (N = 13 306 [5.8%]). A similar pattern was observed for admission to intensive care (UC: N = 8 [2.51%], RR = 27.88 [95% CI 13.88–56.00]; CD: N = 3 [1.52%], RR = 16.92 [95% CI 5.46–52.46]). After a median of 5.1 months (interquartile range [IQR] 4.5–7.9), 58 [42.3%] and 39 [45.9%] patients with UC and CD, respectively, reported persisting symptoms which were independently associated with discontinuation of immunosuppressive therapies during COVID-19 (odds ratio [OR] = 1.50 [95% CI 1.07–10.22], p = 0.01) and severe COVID-19 (OR = 2.76 [95% CI 1.05–3.90], p = 0.04), but not with age or presence of comorbidities.ConclusionIn this population-based study of 516 patients with IBD and COVID-19, 13.6% needed hospitalization and 2.1% required intensive care. Furthermore, sequelae were frequent, affecting 43.7% of COVID-19-infected patients. These findings might have implications for planning the healthcare of patients in the post-COVID-19 era. |
|---|---|
| ISSN: | 18764479 18739946 |
| DOI: | 10.1093/ecco-jcc/jjab192 |